Leadership & Pay ·
Legend Biotech Corporation appointed Alan Bash as Interim Chief Executive Officer effective July 24, 2026
LEGNLegend Biotech Corp
Legend Biotech Corporation appointed Alan Bash as Interim Chief Executive Officer effective July 24, 2026. The Compensation Committee approved a bi-weekly cash compensation of $12,019 for Mr. Bash, payable with each paycheck starting July 27, 2026, in addition to his existing role as President of the CARVYKTI Business Unit. Furthermore, the company granted him restricted stock units valued at $50,000 on August 14, 2026, vesting over three years with one-third vesting annually on the anniversaries of July 27, 2026. Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of CAR T-cell therapies for cancer treatment.